CN118871134A - 用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA - Google Patents

用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA Download PDF

Info

Publication number
CN118871134A
CN118871134A CN202380027077.5A CN202380027077A CN118871134A CN 118871134 A CN118871134 A CN 118871134A CN 202380027077 A CN202380027077 A CN 202380027077A CN 118871134 A CN118871134 A CN 118871134A
Authority
CN
China
Prior art keywords
ires
orf
plasmid vector
encoding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380027077.5A
Other languages
English (en)
Chinese (zh)
Inventor
帕通彭·黄特拉孔盖特
苏拉杰·洪根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Office Of National Higher Education Science Research And Innovation Policy Committee
Biological Exploration Co ltd
Mahidol University
Original Assignee
Office Of National Higher Education Science Research And Innovation Policy Committee
Biological Exploration Co ltd
Mahidol University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Office Of National Higher Education Science Research And Innovation Policy Committee, Biological Exploration Co ltd, Mahidol University filed Critical Office Of National Higher Education Science Research And Innovation Policy Committee
Publication of CN118871134A publication Critical patent/CN118871134A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380027077.5A 2022-03-21 2023-03-21 用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA Pending CN118871134A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TH2201001686 2022-03-21
TH2201001686 2022-03-21
PCT/TH2023/000003 WO2023182948A1 (en) 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression

Publications (1)

Publication Number Publication Date
CN118871134A true CN118871134A (zh) 2024-10-29

Family

ID=86054332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380027077.5A Pending CN118871134A (zh) 2022-03-21 2023-03-21 用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA

Country Status (6)

Country Link
US (1) US20250243507A1 (https=)
EP (1) EP4496598A1 (https=)
JP (1) JP2025509106A (https=)
CN (1) CN118871134A (https=)
AU (1) AU2023240827A1 (https=)
WO (1) WO2023182948A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026006644A1 (en) * 2024-06-26 2026-01-02 Emervax, Inc. Circular mrna yellow fever vaccine
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites
CN119464284B (zh) * 2024-09-29 2026-02-13 复旦大学附属肿瘤医院 一种用于免疫细胞高效蛋白表达的环形rna疫苗平台及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2996697B1 (en) 2013-05-15 2019-06-26 Robert Kruse Intracellular translation of circular rna
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
BR112021023411A2 (pt) 2019-05-22 2022-02-01 Massachusetts Inst Technology Composições e métodos de rna circular
CN114981409A (zh) * 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
JP7851254B2 (ja) * 2020-03-20 2026-04-24 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
AU2021269137A1 (en) * 2020-05-08 2022-12-15 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2021236855A1 (en) * 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
IL298362A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
AU2021300378A1 (en) * 2020-07-01 2023-01-19 Elevatebio Technologies, Inc. Compositions and methods for cellular reprogramming using circular RNA
US20230346921A1 (en) * 2020-08-21 2023-11-02 Peking University Circular rna vaccines and methods of use thereof
AU2021336976A1 (en) * 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
BR112023023642A2 (pt) * 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
CN115404240A (zh) * 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
TW202317767A (zh) * 2021-06-10 2023-05-01 美商歐納醫療公司 環狀rna組合物及方法
CN115702940A (zh) * 2021-08-05 2023-02-17 苏州科锐迈德生物医药科技有限公司 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
EP4496598A1 (en) 2025-01-29
JP2025509106A (ja) 2025-04-11
AU2023240827A1 (en) 2024-07-18
US20250243507A1 (en) 2025-07-31
WO2023182948A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CN118871134A (zh) 用于增强蛋白质表达的内部核糖体进入位点（IRES）、质粒载体和环状mRNA
AU2019280583B2 (en) Circular RNA for translation in eukaryotic cells
US11046975B2 (en) Bicistronic expression vector for antibody expression and method for producing antibody using same
Yu et al. Optimized circular RNA vaccines for superior cancer immunotherapy
KR20220159479A (ko) 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
JP2025535080A (ja) タンパク質を発現するための人工的なポリヌクレオチド
CN117645996A (zh) 核酸5’utr分子及其用途
CN117821508B (zh) 一种编码NGF蛋白的工程化circRNA、药物组合物及其制备方法和应用
WO2026011826A1 (zh) 特异性识别cd276的核酸适体及其应用
CN117205309B (zh) 一种流感免疫原组合物和制备方法及其用途
CN119752906B (zh) 一种5’utr及其应用
HK40116935A (zh) 用於增强蛋白质表达的内部核糖体进入位点(ires)、质粒载体和环状mrna
CN118652889A (zh) 一种环状核酶系统及其应用
Dong et al. Application of HPAA-RGD/si-circICA1 in the treatment of invasive thyroid cancer through targeting of the miR-486-3p/SERPINA1 axis
AU2023201630B2 (en) Circular RNA for translation in eukaryotic cells
CN119752905B (zh) 一种utr元件及其应用
CN114807376B (zh) 一种胶质瘤生物标志物及其应用
US20260125673A1 (en) Artificial polynucleotides for expressing proteins
CN121226501A (zh) 一种自复制元件、自复制rna分子及其用途
HK40077179B (zh) 一种修饰的核酸及其应用
CN119639754A (zh) mRNA及其合成方法、mRNA疫苗、加帽RNA、体外转录反应液
WO2024198028A1 (zh) 一种重组核酸载体及其在制备环状rna分子中的用途
CN119709752A (zh) 一种介导uga密码子通读的靶向性secis rna及其应用
CN119662641A (zh) 5’utr序列及其用途
WO2026007832A1 (zh) 一种增强外源基因表达的3'utr及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116935

Country of ref document: HK